Trending Topics


Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today’s headlines.
Contact a media coordinator

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.
Monday, September 16, 2019
Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.
Monday, September 9, 2019
Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help doctors identify children who are at risk for disease recurrence and precisely tailor treatment to overcome drug resistance.
Thursday, August 8, 2019
See all trending topics

Press Releases


After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.
Tuesday, September 10, 2019
Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared new data from a survey of members of the Society of Gynecologic Oncology (SGO) showing that sexual harassment and observed gender discrimination continue to be significant issues in the medical community. The results of the study found that more than 60 percent of gynecologic oncologists had experienced sexual harassment, while only 10 percent of survey respondents reported the incident. The findings were presented as part of the press program for this year’s annual meeting of the American Society of Clinical Oncology (ASCO).
Monday, June 3, 2019
Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.
Wednesday, April 10, 2019
See all press releases

On Our Blog


An MSK study explains how the drug selinexor, which was recently approved to treat multiple myeloma and is being tested in many other tumor types, stops cancer.
Monday, September 16, 2019
Dennis Chi debunks some common myths that he has heard about ovarian cancer.
Monday, September 16, 2019
Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.
Friday, September 13, 2019
See all blog posts

Media Coverage


Memorial Sloan Kettering Cancer Center announced Tuesday that, following a nationwide search, MSK’s Lisa DeAngelis has been named Physician-In-Chief and Chief Medical Officer.
Wednesday, September 11, 2019
Men do get breast cancer, but they account for fewer than 1 percent of patients and often receive inadequate care. MSK’s Larry Norton is quoted.
Monday, September 9, 2019
More women may benefit from gene testing for hereditary breast or ovarian cancer, especially if they’ve already survived cancer once, an influential health group recommended Tuesday. MSK’s Mark Robson is quoted.
Wednesday, August 21, 2019
See all media coverage

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at

Jeanne D'Agostino
Director, Media and Public Relations
Emily O'Donnell
Media Relations Manager, Surgery
Courtney Nowak
Media Relations Manager, Regional Care Network
Caitlin Hool
Senior Manager, Media Relations and Partnerships
Nicole H. McNamara
Senior Media Strategist
Rebecca Williams
Media Strategist
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 am to 5:00 pm.
After hours, please contact the hospital’s page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.

Contact our Media Staff